atai Life Sciences is a technology company.
atai Life Sciences has raised $173.0M across 3 funding rounds.
Key people at atai Life Sciences.
atai Life Sciences has raised $173.0M in total across 3 funding rounds.
# atai Life Sciences: Correcting the Classification
atai Life Sciences is not a technology company—it is a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments, particularly psychedelic-based therapies[1][4].
atai Life Sciences operates as a biopharmaceutical platform company with a mission to develop highly effective mental health treatments that address significant unmet medical needs[1][4]. Rather than building software or technology products, the company acquires, incubates, and advances drug candidates through clinical trials, with a particular focus on psychedelic-based neuroplastogens and rapid-acting psychiatric interventions[1][4].
The company serves patients suffering from mental health disorders, addressing a critical global need: over one billion people live with mental health conditions worldwide, yet most lack access to effective care[3]. atai's approach centers on compounds with prior evidence in human use to minimize development risk, pooling resources to accelerate responsible drug development[2].
atai operates at the intersection of psychiatric innovation and the emerging psychedelic medicine field. The company is positioned to capitalize on growing clinical evidence supporting psychedelic-assisted therapies for treatment-resistant depression and social anxiety disorder[4]. By developing interventional psychiatry solutions designed to integrate into existing healthcare systems, atai addresses both the scientific frontier and the practical challenge of scalable mental health treatment delivery[4].
atai's success hinges on advancing its clinical pipeline through regulatory approval while demonstrating that psychedelic-based treatments can achieve sustained behavioral change in mental health patients[1][4]. The 2025 combination with Beckley Psytech positions the company as a leader in rapid-acting, accessible psychedelic treatments, with potential first-in-class and best-in-class assets in development[4]. As mental health treatment paradigms shift toward novel neuroplastogenic compounds, atai's focused approach to evidence-based drug development could reshape how psychiatric conditions are treated globally.
Key people at atai Life Sciences.
atai Life Sciences has raised $173.0M in total across 3 funding rounds.
atai Life Sciences's investors include Endeavor8, Endeavor Venture Funds, Northpond Ventures, Wilbur-Ellis [Cavallo], Alumni Ventures, Atreides Management, Audrey Capital, Bascom Ventures, BITKRAFT Ventures, Future Ventures, Grit Capital Partners, Lightspeed Venture Partners.
atai Life Sciences has raised $173.0M across 3 funding rounds. Most recently, it raised $30.0M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $30.0M Series C | Endeavor8, Endeavor Venture Funds, Northpond Ventures, Wilbur-Ellis [Cavallo] | |
| Sep 1, 2020 | $130.0M Series C | Alumni Ventures, Atreides Management, Audrey Capital, Bascom Ventures, BITKRAFT Ventures, Endeavor Venture Funds, Future Ventures, Grit Capital Partners, Lightspeed Venture Partners, Mayfield, Negev Capital, PsyMed Ventures, Ryan Zurrer, VSC Ventures, What If Ventures, Daria Derkach, Robert Goldberg, Sahin Boydas, Ted Moskovitz | |
| Feb 1, 2019 | $13.0M Series B | Endeavor8, Endeavor Venture Funds, Negev Capital, Northpond Ventures, Wilbur-Ellis [Cavallo], David Ebsworth, Peter Keen |
